Icrucumab clinical trials
Also written IMC-18F1 and LY3012212.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses Icrucumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Icrucumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis CarcinomaCompletedPhase 2Eli Lilly and CompanyNCT01282463Written as Icrucumab
- Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer PatientsCompletedPhase 2Eli Lilly and CompanyNCT01234402Written as IMC-18F1
- A Study of Ramucirumab or Icrucumab in Colorectal CancerCompletedPhase 2Eli Lilly and CompanyNCT01111604Written as Icrucumab
- Safety Study of IMC-18F1,to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard TherapyCompletedPhase 1Eli Lilly and CompanyNCT00782002Written as IMC-18F1
Codes
What other systems call Icrucumab · ClinicalTrials.gg INT000897
- MeSH (NLM) C000626257IcrucumabOne source NLM
- UNII (FDA) T7H0B1R64UICRUCUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5986756IcrucumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79808IcrucumabOne source FDA
- DrugBank DB14824One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626257 | Icrucumab | One source NLM |
| UNII (FDA) | T7H0B1R64U | ICRUCUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5986756 | Icrucumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79808 | Icrucumab | One source FDA |
| DrugBank | DB14824 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.